Suppr超能文献

放疗后恶性胸膜间皮瘤的外科治疗(SMART):来自单中心、2 期试验的最终结果。

Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.

机构信息

Department of Radiation Oncology, University Health Network, University of Toronto, ON, Canada.

Princess Margaret Cancer Centre, Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, ON, Canada.

出版信息

Lancet Oncol. 2021 Feb;22(2):190-197. doi: 10.1016/S1470-2045(20)30606-9. Epub 2021 Jan 12.

Abstract

BACKGROUND

A novel approach for managing malignant pleural mesothelioma, surgery for mesothelioma after radiotherapy (SMART), consisting of a short accelerated course of high-dose, hemithoracic, intensity modulated radiotherapy (IMRT) followed by extrapleural pneumonectomy was developed. The aim of this study was to evaluate the clinical feasibility of the SMART protocol.

METHODS

In this single-centre, phase 2 trial, patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, with histologically proven, resectable, cT1-3N0M0 disease who had previously untreated malignant pleural mesothelioma were eligible for inclusion. Patients received 25 Gy in five daily fractions over 1 week to the entire ipsilateral hemithorax with a concomitant 5 Gy boost to high risk areas followed by extrapleural pneumonectomy within 1 week. Adjuvant chemotherapy was offered to patients with ypN+ disease on final pathology. The primary endpoint was feasibility, which was defined as the number of patients with 30-day perioperative treatment-related death (grade 5 events) or morbidity (grade 3 or 4 events). A key secondary endpoint was cumulative incidence of distant recurrence. The final analysis was done on an intention-to-treat basis (including all eligible patients). This trial is registered with ClinicalTrials.gov, NCT00797719.

FINDINGS

Between Nov 1, 2008, and Oct 31, 2019, 102 patients were enrolled onto the trial and 96 eligible patients were treated with SMART on protocol and included in the analysis. Extrapleural pneumonectomy was done at a median of 5 days (range 2-12) after completing IMRT. 47 (49%) patients had 30-day perioperative grade 3-4 events and one (1%) patient died within 30 days perioperatively (grade 5 event; pneumonia). After a median follow-up of 46·8 months (IQR 13·4-61·2), the 5-year cumulative incidence of distant recurrence was 62 (63·3% [95% CI 52·3-74·4]). The most common first sites of recurrence were the contralateral chest (33 [46%] of 72 patients) and the peritoneal cavity (32 [44%]).

INTERPRETATION

Results from this study suggest that extrapleural pneumonectomy after radiotherapy can be done with good early and long-term results. However, minimising grade 4 events on the protocol is technically demanding and might affect survival beyond the post-operative period.

FUNDING

Princess Margaret Hospital Foundation Mesothelioma Research Fund.

摘要

背景

一种治疗恶性胸膜间皮瘤的新方法,即放疗后行胸膜切除术(SMART),包括短程加速高剂量半胸部调强放疗(IMRT),随后在 1 周内行胸膜外全肺切除术。该研究旨在评估 SMART 方案的临床可行性。

方法

在这项单中心、2 期临床试验中,纳入了年龄在 18 岁及以上、东部合作肿瘤学组体力状态为 0-2 分、经组织学证实、可切除、cT1-3N0M0 疾病的患者,且患者患有先前未经治疗的恶性胸膜间皮瘤。患者接受 25 Gy 剂量,每日 5 次,共 5 天,照射整个同侧半胸部,同时给予 5 Gy 高剂量区域照射,随后在 1 周内行胸膜外全肺切除术。根据最终病理结果,对 ypN+疾病的患者给予辅助化疗。主要终点是围手术期治疗相关 30 天内死亡率(5 级事件)或发病率(3 级或 4 级事件)的患者人数。次要终点是远处复发的累积发生率。最终分析采用意向治疗(包括所有合格的患者)。该试验在 ClinicalTrials.gov 上注册,注册号为 NCT00797719。

结果

2008 年 11 月 1 日至 2019 年 10 月 31 日期间,共有 102 名患者入组该试验,其中 96 名符合 SMART 方案且接受协议治疗的合格患者纳入分析。在完成 IMRT 后中位 5 天(范围 2-12)进行胸膜外全肺切除术。47(49%)名患者在 30 天围手术期发生 3 级或 4 级事件,1 名(1%)患者在围手术期 30 天内死亡(5 级事件;肺炎)。中位随访 46.8 个月(IQR 13.4-61.2)后,5 年远处复发累积发生率为 62(63.3%[95%CI 52.3-74.4])。最常见的首发部位是对侧胸部(72 名患者中有 33 名[46%])和腹膜腔(32 名患者中有 32 名[44%])。

结论

该研究结果表明,放疗后行胸膜外全肺切除术可获得良好的近期和远期结果。然而,在方案中减少 4 级事件的发生率在技术上具有挑战性,并且可能会影响术后的生存。

资金

玛格丽特公主医院基金会间皮瘤研究基金。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验